Von Eschenbach nomination on track?
This article was originally published in The Gray Sheet
Executive Summary
Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) drop their hold on Acting FDA Commissioner Andrew von Eschenbach's nomination to the permanent post Aug. 24 following the agency's decision to make Barr Pharmaceuticals' Plan B emergency contraceptive available over-the-counter for women age 18 and older (1"The Gray Sheet" Aug. 7, 2006, p. 17). However, at least one Republican is said to be considering a hold in opposition to the Plan B decision, according to a Senate Health, Education, Labor & Pensions Committee staffer. Committee Chair Michael Enzi (R-Wyo.) has not yet scheduled a vote on the nominee, the staffer says. Enzi is reviewing the approval decision and gauging committee members' reactions to it...
You may also be interested in...
Panel to vote on von Eschenbach
Senate Health Education Labor & Pensions Committee schedules Sept. 20 vote on nomination of Andrew von Eschenbach to be permanent FDA commissioner despite the prospect of future holds. Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.) have threatened to place holds on the nomination once it reaches the Senate floor due to the lack of a drug importation program and continued marketing of Danco Laboratories' abortion pill Mifeprex (mifepristone), respectively. Democratic Sens. Hillary Clinton (N.Y.) and Patty Murray (Wash.) only recently released their hold on the nominee following FDA's approval of Plan B for dual Rx/OTC status (1"The Gray Sheet" Aug. 28, 2006, In Brief)...
Von Eschenbach Nomination Still Stalled After Some Movement On Plan B
Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.